IQV

IQV

IQV

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2025 Q2	Sep 4, 2025	Broyhill Asset Management	3.7%	6.6%	AVTR, DLTR, FI, IQV, PM, SCHW	dispersion, Mean reversion, small caps, stock picking, valuation gaps	The commentary emphasizes record valuation dispersion and fading market leadership as fertile ground for active stock pickers. Smaller and mid-sized companies trading at discounts to fundamentals are highlighted as key opportunities. Dispersion is positioned as a catalyst for mean reversion and long-term outperformance.		View
2025 Q2	Jul 23, 2025	Cedar Creek Partners	5.8%	15.1%	ENDI, IQV, MCBS, PCHM, PHIG, PROM, SLRC, SODI	Balance Sheets, Intrinsic Value, Mean reversion, Patience, value	The letter emphasizes disciplined value investing focused on businesses trading below intrinsic value due to temporary dislocations or neglect. The manager highlights patience, balance sheet strength, and downside protection as critical in a market dominated by momentum and macro noise. Cedar Creek argues that normalized earnings power and mean reversion provide attractive long-term return potential.	ENDI PROM	View
2025 Q2	Jul 22, 2025	Harris Associates Concentrated Strategy	3.9%	3.7%	COF, COP, CRL, CRM, GOOG, ICLR, IQV, SCHW, WTW	downside protection, fundamentals, Mean reversion, valuation dispersion, Value Investing	The letter centers on intrinsic value investing amid extreme valuation dispersion between popular growth stocks and unloved franchises. Management argues that patience and concentration in discounted, high-quality businesses will be rewarded as fundamentals reassert themselves. The strategy emphasizes downside protection and long-term mean reversion rather than short-term momentum.	IQV COP GOOG COF SCHW	View
2024 Q1	Apr 15, 2024	Oakmark Global Select Fund	8.8%	0.0%	CHTR, CNC, FI, IQV, RKT LN	-			View
2025 Q1	Mar 31, 2025	Harris Associates Concentrated Strategy	-0.1%	-0.1%	COP, DE, FIZN, GOOG, ICE, IQV, MOH	-			View
2025 Q4	Feb 12, 2026	Artemis US Select Fund (Class I Accumulation Shares GBP)	7.0%	10.0%	AMAT, AMD, AXON, CAH, CTVA, ETN, IQV, KO, LLY, LYV, META, MU, NVT, PH, RCL, WDC	AI, growth, healthcare, Pharmaceuticals, semiconductors, technology, US Equities	The manager expects greater dispersion between AI winners and losers, having demonstrated ability to analyze and identify these groups over the past three years. AMD rallied after announcing significant AI-related partnerships, positioning the fund to benefit from continued AI trade evolution. Healthcare is a sector the manager is optimistic about and has been building exposure to following an extended period of underperformance. Eli Lilly's obesity and diabetes franchise continues to exceed expectations, particularly with Mounjaro sales ahead of estimates. The fund increased semiconductor exposure during the quarter, with Micron completely selling out of memory chips and forecasting higher profit margins. Applied Materials was added as a new position in semiconductor wafer fabrication equipment.		View
2025 Q4	Feb 12, 2026	Broyhill Asset Management	0.0%	0.0%	AVTR, BAX, DLTR, FI, FUN, IQV, PM, RKT.L, TMO, WOSG.L	AI, Concentration, defensives, Europe, fundamentals, momentum, Speculation, value	The AI capital cycle has created extreme market concentration and speculative momentum, with AI-related stocks accounting for 75% of S&P 500 returns since ChatGPT launched. The manager views this as a bubble similar to historical infrastructure buildouts like railroads and electricity, where early investors suffered catastrophic losses while benefits ultimately accrued to users rather than producers. Current AI capex spending approaches 2.1% of GDP, nearing levels that coincided with previous market peaks. Value stocks are trading at some of the widest discounts on record, with the portfolio positioned in businesses trading at substantial discounts to normalized earnings power. The manager believes this disconnect reflects pessimism and exhaustion rather than permanent impairment, creating an extremely promising starting point for long-term outperformance as fundamentals reassert themselves. Momentum has been the single defining force across equity markets, with performance increasingly driven by narratives rather than fundamentals. The current cycle has been one for the record books, with the two years leading up to 2025 being the second strongest on record for momentum after the dot-com era. The manager expects mean reversion to eventually favor value strategies. Global defensive sectors have fallen to their lowest weighting since 2000, trading at discounts to both the market and their own histories amid deteriorating sentiment and unusually high short interest. These sectors offer significant upside potential and provide defense, as companies selling basic necessities tend to shine when the rest of the market is in trouble.	RKT LN WOSG LN FUN AVTR FISV DLTR IQV PM	View
2024 Q4	Dec 31, 2024	Oakmark Select Fund	6.0%	14.2%	ABNB, EFX, IQV, KDP, PAYC	-			View
2024 Q4	Dec 31, 2024	Hardman Johnston Global Equity	-0.2%	22.0%	BAC, CTVA, ELAN, HWM, IQV, LEN, MELI, OLED, SCHW, TEAM, UBER, VRT	-			View
2025 Q3	Oct 28, 2025	Harris Associates Concentrated Strategy	2.4%	6.2%	CRM, GOOG, IQV, KDP, MOH, WBD	Artificial Intelligence, Cloud, healthcare, Media, U.S. Equities	U.S. equities rose on tech strength, with key contributors Warner Bros Discovery and Alphabet benefiting from M&A speculation and AI-driven cloud growth. IQVIAs analytics and clinical research platform also advanced due to next-gen data capabilities. While detractors included Keurig Dr Pepper and Molina Healthcare, management remains focused on concentrated, high-conviction holdings tied to AI innovation and healthcare recovery.	CRM MOH KDP IQV GOOGL WBD CRM MOH KDP IQV GOOGL WBD	View
2024 Q3	Oct 28, 2024	Parnassus Mid Cap Growth Fund	8.6%	13.3%	ADSK, ARNB, BILL, BIRK, GWRE, H, IBKR, IQV, JBHT, LPLA, MRNA, MTN, NET, NTR, ONON, RRR, SHOP, SPOT, TSLA	-			View
2025 Q3	Oct 16, 2025	Platinum International Fund	9.0%	-	ASML, BABA, IQV, TSM	Artificial Intelligence, China, healthcare, semiconductors, technology	The funds outperformance stemmed from AI-related semiconductor holdings and a rebound in healthcare names after regulatory clarity. It highlights balanced positioning between the U.S. and China, with Chinese tech valuations remaining attractive. Platinum expects sustained AI investment and normalization in pharmaceutical research spending to drive multi-sector growth.	TSM	View
2025 Q3	Oct 16, 2025	Platinum Global Fund (Long Only)	10.0%	-	ASML, BABA, IQV, TSM	Artificial Intelligence, China, consumer, semiconductors, technology	The fund attributes outperformance to AI-driven semiconductor exposure and recovery in Chinese equities. It sees continued momentum in global technology leaders like TSMC, ASML, and Micron, alongside selective opportunities in undervalued Chinese tech firms. Platinum remains constructive on AI investment while emphasizing balanced exposure between U.S. and China as AI and consumer trends converge.	IQV UN	View
2025 Q4	Jan 14, 2026	Hardman Johnston Large Cap Equity	4.3%	0.0%	7269.T, AMZN, AZN, BDX, CCO.TO, CMCSA, EL, EW, GOOGL, HDB, ILMN, IQV, MA, META, MMC, PYPL, SCHW, SLB, SN, TMUS	AI, Genomics, growth, healthcare, large cap, Lithium, technology	AI remains an important driver for portfolio performance, with investments made years ago benefiting from the surge in AI spending. The manager sees AI as particularly relevant in healthcare where it can help achieve both innovation and efficiency while controlling healthcare spending growth. Albemarle is benefiting from a surge in lithium prices due to near-term production disruptions at competitors, improving outlook for global EV penetration, and investment in batteries as energy storage platforms for alternative energy supplies. Illumina, with almost 70% market share in gene sequencing, has weathered a storm of life science funding cuts and competitive entries. While challenges remain, they are well positioned to benefit from any acceleration in clinical and research spending in life sciences.	OLED AEIS ILMN ALB	View
2025 Q4	Jan 13, 2026	Oakmark Global Select Fund	2.9%	20.7%	BABA, BAYRY, CHTR, CNHI, GOOGL, IQV, MBG.DE, RHHBY, SNY	China, Europe, global, healthcare, Pharmaceuticals, technology, value	The fund is positioned in pharmaceutical companies with strong fundamentals and growth potential. Bayer benefited from positive drug trial results and potential Supreme Court review of litigation matters. Sanofi was added as a new position, featuring the blockbuster drug Dupixent and strong R&D pipeline despite being weighed down by vaccine market volatility and patent cliff concerns. The fund maintains exposure to Chinese e-commerce through Alibaba despite near-term headwinds. While the core e-commerce business performs well and cloud revenue growth accelerates, the company faces earnings pressure from Quick Commerce subsidies. The managers believe losses will reduce over time and see long-term positioning in Chinese AI as valuable.	SAN FP BABA BAYN GR	View
2025 Q4	Jan 13, 2026	Oakmark Select Fund	8.4%	14.3%	CHTR, EFX, GLIBA, GOOGL, IQV, LBRDK, NFLX, PAYC, TRGP, WBD	large cap, M&A, Media, Midstream, undervalued, value	Warner Bros Discovery was the top contributor as multiple parties submitted acquisition offers, with Netflix acquiring the Streaming and Studios business while Global Networks spins to shareholders. Paramount Skydance made a $30 per share offer for the entire company, creating a bidding war that unlocked shareholder value. Targa Resources represents a leading midstream natural gas and NGL company controlling 90% of fractionation capacity at Mont Belvieu hub. The company benefits from cost advantages, barriers to entry, and generates 90% of earnings through multi-year fee-based arrangements providing protection against oversupply. The fund continues to find attractive opportunities to invest in undervalued companies across various industries, including areas left behind in the momentum rally. Targa was purchased at a discount to peers based on normalized earnings power and intrinsic value estimates.	TRGP PAYC WBD	View
2025 Q4	Jan 13, 2026	Oakmark Global Fund	5.2%	21.2%	005930.KS, BABA, CHTR, CNHI, DSV.CO, GM, IQV, IT, MBG.DE, MDLZ	consumer, global, healthcare, Performance, semiconductors, technology, value	Samsung Electronics was the top contributor as earnings staged a sharp recovery due to strength in its core semiconductor business. The company's High Bandwidth Memory product lineup has continued to improve under new management, positioning Samsung as one of the world's leading semiconductor companies with a long runway for future growth. Alibaba Group was the top detractor despite its core E-commerce business continuing to perform well and Cloud revenue growth accelerating. The company was negatively impacted by significant spending on subsidies to grow their Quick Commerce business, though losses are expected to be reduced over time. Mondelez International is a global snacking powerhouse with leading market share positions in crackers, cookies and chocolate. The company possesses a unique global footprint that over-indexes to snacking occasions, benefiting from robust pricing power, low private label competition and rising per capita consumption.	MDLZ IT BABA 005930 KS	View
2023 Q3	Sep 30, 2023	Oakmark Select Fund	8.1%	0.0%	IQV	-			View
2023 Q2	Jul 21, 2023	Cedar Creek Partners	-0.1%	4.8%	CZBS, IQV, MFBP, PDRX, PROM, ROYTL, SLRC, SODI	-			View
2023 Q2	Jun 30, 2023	Oakmark Fund- International Small Cap	7.4%	0.0%	BAX, CE, CSL, FIZN, IQV	-			View
2023 Q2	Jun 30, 2023	Oakmark Global Fund	7.5%	0.0%	CRBG, DHR, IQV	-			View
2025 Q1	Apr 15, 2025	Cedar Creek Partners	8.7%	8.7%	CZBS, ENDI, EVRC, FIEB, IQV, MCBS, PCHM, PDRX, PROM, SLBK, SLRC, SODI, WCRS	-			View
2023 Q4	Jan 23, 2024	Cedar Creek Partners	-0.1%	4.8%	CZBS, IQV, PCHM, PDRX, PROM, ROYTL, SKAS, SODI, UBAB	-			View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Feb 21, 2026	Fund Letters	Christopher R. Pavese	IQVIA Holdings Inc.	Health Care	Life Sciences Tools & Services	Bull	New York Stock Exchange	backlog, Biotech, Clinicaltrials, Outsourcing, recovery	View Pitch
Jan 8, 2026	Fund Letters	Tony Coniaris	IQVIA Holdings Inc.	Health Care	Life Sciences Tools & Services	Bull	New York Stock Exchange	analytics, Cro, Data, growth, lifesciences, Outsourcing	View Pitch
Jan 8, 2026	Fund Letters	C.T. Fitzpatrick	IQVIA Holdings, Inc.	Health Care	Life Sciences Tools & Services	Bull	New York Stock Exchange	analytics, backlog, biopharma, Margins, Outsourcing, Subscriptions, Trials	View Pitch
Nov 29, 2025	Fund Letters	Tony Coniaris	IQVIA Holdings Inc.	Health Care	Health Care Services	Bull	NYSE	AI, Data Analytics, Digital transformation, growth, margin expansion, pharma, research	View Pitch
Nov 28, 2025	Fund Letters	Tony Coniaris	IQVIA Holdings Inc.	Health Care	Health Care Services	Bull	NYSE	AI, Data Analytics, Digital transformation, growth, margin expansion, pharma, research	View Pitch
Sep 1, 2025	Substack	Borlaug	IQVIA Holdings Inc.	Healthcare	Diagnostics & Research	Bull		capital deployment, contract research organization, CRO industry, EPS growth, FCF growth, IQVIA Holdings Inc., ROIC, S&P 500 discount, secular growth drivers, valuation dislocation	View Pitch
Aug 7, 2025	Seeking Alpha	Mario Silva	IQVIA Holdings	Health Care	Diagnostics & Research	Neutral	NYSE	—	View Pitch
Aug 7, 2025	Seeking Alpha	Harris Oakmark	IQVIA Holdings	Health Care	Diagnostics & Research	Bull	NYSE	—	View Pitch

BSD Shareholders of IQV

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: